Publications

Development of Dl1.72, a Novel Anti-Dll1 Antibody with Anti-Tumor Efficacy Against Estrogen Receptor-Positive Breast Cancer

AuthID
P-00V-CD5

Author(s)

Silva, G

Sales Dias, J

Casal, D

Alves, S

Domenici, G

Barreto, C

Matos, C

Lemos, AR

Matias, AT

Kucheryava, K

[+1]·

Moita, MR

Braga, S

Sousa, PMF

Barbas, A

Document Type

Article

Year published

2021

Published

in CANCERS

Volume: 13, Issue: 16, Pages: 4074 (20)

Indexing

Wos^®

Scopus^®

Crossref^®4

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.3390/cancers13164074

SCOPUS: 2-s2.0-85112348312

Wos: WOS:000689049500001

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

All authors

Name Order	Name	Name Order	Name	Name Order	Name
1	Silva, G;	2	Sales Dias, J;	3	Casal, D;
4	Alves, S;	5	Domenici, G;	6	Barreto, C;
7	Matos, C;	8	Lemos, AR;	9	Matias, AT;
10	Kucheryava, K;	11	Ferreira, A;	12	Moita, MR;
13	Braga, S;	14	Brito, C;	15	Cabral, MG;
16	Casalou, C;	17	Barral, DC;	18	Sousa, PMF;
19	Videira, PA;	20	Bandeiras, TM;	21	Barbas, A;

Development of Dl1.72, a Novel Anti-Dll1 Antibody with Anti-Tumor Efficacy Against Estrogen Receptor-Positive Breast Cancer

Useful Links

Get Help

Federated Authentication (Click on the image)

Development of Dl1.72, a Novel Anti-Dll1 Antibody with Anti-Tumor Efficacy Against Estrogen Receptor-Positive Breast Cancer

Useful Links

Get Help